Also trades as: NAMS (NASDAQ) · $vol 30M
NAMSW NASDAQ
NewAmsterdam Pharma Company N.V.
1W: +11.0%
1M: -23.4%
3M: -46.0%
YTD: -45.2%
1Y: -26.1%
3Y: +542.1%
5Y: +1542.9%
$12.70
+0.05 (+0.40%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
Income Trends
Revenue
$23M
-50.6% ▼
Gross Profit
$22M
-50.7% ▼
Operating Income
-$226M
-28.0% ▼
Net Income
-$204M
+15.6% ▲
EPS (Diluted)
$-1.75
+31.6% ▲
EBITDA
-$242M
-0.3% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $103M | $14M | $46M | $23M |
| YoY Growth | +0.0% | +0.0% | -86.7% | +257.0% | -50.6% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $59K |
| Gross Profit | $0 | $103M | $14M | $46M | $22M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 99.7% |
| R&D Expenses | $29M | $87M | $159M | $151M | $142M |
| SG&A Expenses | $6M | $20M | $38M | $70M | $106M |
| Operating Expenses | $35M | $106M | $197M | $222M | $248M |
| Operating Income | -$35M | -$4M | -$183M | -$176M | -$226M |
| Operating Margin | — | -3.5% | -1298.6% | -386.9% | -1002.9% |
| Interest Expense | $411K | $287K | $7M | $0 | $0 |
| Income Before Tax | -$42M | -$23M | -$177M | -$242M | -$204M |
| Tax Expense | $0 | $0 | $27K | -$1K | $0 |
| Net Income | -$42M | -$23M | -$177M | -$242M | -$204M |
| Net Margin | — | -22.0% | -1255.8% | -530.3% | -905.7% |
| EPS (Diluted) | $-3.34 | $-1.11 | $-2.15 | $-2.56 | $-1.75 |
| EBITDA | -$41M | -$22M | -$177M | -$241M | -$242M |
| Shares Outstanding | 18M | 19M | 82M | 94M | 114M |